Cognition Therapeutics Launches Expanded Access Program for Zervimesine

Cognition Therapeutics ( (CGTX) ) just unveiled an announcement.

On June 3, 2025, Cognition Therapeutics announced the launch of an expanded access program (EAP) for zervimesine in patients with dementia with Lewy bodies, funded by an anonymous philanthropic donation. This program, led by Dr. James Galvin, will initially accommodate approximately 30 individuals across eight U.S. sites, providing them with 100 mg of oral zervimesine daily for about a year. The initiative marks a significant step in Cognition’s efforts to offer potential therapeutic benefits to DLB patients, enhancing its industry positioning and stakeholder engagement.

The most recent analyst rating on (CGTX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cognition Therapeutics stock, see the CGTX Stock Forecast page.

Spark’s Take on CGTX Stock

According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.

Cognition Therapeutics is currently facing major financial challenges with persistent losses and cash flow issues. Technical indicators provide mixed signals with short-term momentum but long-term caution. Valuation remains a concern with negative earnings and no dividend yield. Although the earnings call highlighted some strategic progress, significant concerns like NASDAQ compliance and uncertain funding overshadow these advancements. Overall, the stock is a high-risk investment with potential for future improvement if financial and strategic objectives are met.

To see Spark’s full report on CGTX stock, click here.

More about Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. The company is investigating its lead candidate, zervimesine (CT1812), in clinical programs for dementia with Lewy bodies (DLB) and Alzheimer’s disease.

Average Trading Volume: 940,643

Technical Sentiment Signal: Sell

Current Market Cap: $19.65M

Learn more about CGTX stock on TipRanks’ Stock Analysis page.